Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

About Roche Diagnostics Middle East

Roche has taken the unprecedented move of being the first IVD company to have a Management Center and a logistics hub in the Middle East. Roche has extended its ownership of the entire supply chain, quality control and customer support all the way into the centre of the region. This base of operations reinforces the commitment to global Roche Standards and is driven by a full team of vastly experienced specialists offering a complete portfolio of services. With this regional empowerment, Roche has moved its leadership and decision-making closer to its customers and distributors. Roche Diagnostics also recently announced the establishment of a direct sales affiliate in Egypt to better meet the needs of the country's healthcare sector. These investments allow Roche Diagnostics Middle East to develop from being a supplier into becoming the preferred IVD partner for its customers. All trademarks used or mentioned in this release are protected by law.

Our Journey

1
2012

In 2012 Roche Diagnostics solidified there decision to invest heavily in the Middle East. Roche Diagnostics Middle East FZCO (RDME) corporate office was opened in JAFZA in Dubai, UAE. The mission is based on two pillars: extend the reach of the supply chain, and be closer to our customers. RDME identified that highly trained staff was needed to realize its' vision.


2014

2014 was a major milestone year for Roche Diagnostics Middle East FZCO (RDME). This year saw the firm establishment of two mission critical programs. The First is the Regional Customer Support Centre (RCSC). RDME identified that our customers would like to be able to call in to a support centre and get the information needed to troubleshoot situations immediately in the laboratory. In it's first year of operation the RCSC realized a success factor of solving 80% of the requests in 20 minutes or less over the phone, thus helping hospitals and laboratories get back to patients at record pace. The Second was the inception of the Roche Academy - www.rdmeacademy.com. This was the first customer training protal of its kind. It allowed our valued customers to access the Roche portfolio of trainings in order to enhance our customers skills in and around the Roche Diaganostic instruments.

2

3
2016

Going in to 2016 the concept of customer training was in full affect. The number of our customers attending the program was on the rise and leading to a truly appreciated and valued service from Roche Diagnostics Middle East FZCO!

Doing now what patients need next

Create profile to register for our training, events and online certification program